Ipsen to Acquire ImCheck Therapeutics to Advance Promising AML Immunotherapy ICT01

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high t...

October 23, 2025 | Thursday | News
Sharp Commits $100 Million to Expand Sterile and Packaging Capacity Across U.S. and Europe

    Sterile fill/finish capacity added in Lee, MA, and injectable assembly and packaging capacity added in the Netherlands, Belgium, Allent...

October 23, 2025 | Thursday | News
Salvat Secures FDA Approval for Clotic®, the First Targeted Therapy for Otomycosis with Orphan Drug Designation

SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation     Th...

October 22, 2025 | Wednesday | News
BriaCell Partners with Memorial Sloan Kettering to Accelerate Development of Next-Generation Personalized Immunotherapy

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...

October 22, 2025 | Wednesday | News
Minerva Neurosciences Secures up to $200 Million to Advance Roluperidone Through Confirmatory Phase 3 Trial and NDA Resubmission

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...

October 22, 2025 | Wednesday | News
Adcytherix Raises €105 Million Series A to Advance Next-Generation Antibody–Drug Conjugates with Novel Payloads

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...

October 20, 2025 | Monday | News
Agios Pharmaceuticals Receives CHMP Positive Opinion for PYRUKYND® in Treating Alpha- and Beta-Thalassemia

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rar...

October 20, 2025 | Monday | News
Azurity Pharmaceuticals Receives FDA Approval for Ferabright™, the First Iron-Based MRI Contrast Agent for Brain Tumour Imaging

Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...

October 20, 2025 | Monday | News
Kezar Life Sciences Initiates Strategic Review Following FDA Setback on Autoimmune Hepatitis Trial

-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...

October 17, 2025 | Friday | News
Thermo Fisher and OpenAI Unite to Accelerate Drug Development with Frontier AI

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s p...

October 17, 2025 | Friday | News
China NMPA Accepts Belite Bio’s NDA for Tinlarebant with Priority Review Based on Phase 3 DRAGON Interim Data

NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025  Belite Bio, Inc. (NASDAQ...

October 16, 2025 | Thursday | News
SCYNEXIS to Receive $22 Million from GSK as Phase 3 MARIO Study on Invasive Candidiasis Is Terminated

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis...

October 16, 2025 | Thursday | Regulatory
NuCana’s NUC-3373 Plus Pembrolizumab Shows Durable Responses in Heavily Pre-Treated Cancer Patients

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient wi...

October 16, 2025 | Thursday | News
Corventum Secures FDA Clearance for IND of CVT-130 to Prevent Chemotherapy-Induced Cardiotoxicity

-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective,  announced the clea...

October 15, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close